Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 307, Issue 4, 2014, Pages

  Morin, Caroline ^a,b   Hiram, Roddy ^b   Rousseau, Eric ^b   Blier, Pierre U ^c   Fortin, Samuel ^a,c  

^a SCF Pharma   (Canada)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c UNIVERSITÉ DU QUÉBEC À RIMOUSKI   (Canada)

Author keywords

Docosapentaenoic acid; Inflammation; Nuclear factor B; Pulmonary hypertension; Tumor necrosis factor

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; DOCOSAPENTAENOIC ACID; DOCOSAPENTAENOIC ACID MONOACYLGLYCERIDE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KI 67 ANTIGEN; LIPID; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCROTALINE; UNCLASSIFIED DRUG; VASCULOTROPIN; 1-O-DOCOSAPENTAENOYLGLYCEROL; MMP2 PROTEIN, RAT; MMP9 PROTEIN, RAT; MONOACYLGLYCEROL; UNSATURATED FATTY ACID; VASCULOTROPIN A;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFICACY; HEART RIGHT VENTRICLE HYPERTROPHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INJECTION; LIPID ANALYSIS; LIPID BLOOD LEVEL; MALE; MORPHOMETRICS; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; TISSUE HOMOGENATE; TREATMENT DURATION; ANIMAL; ARTERIOLE; DRUG EFFECTS; GENETICS; HYPERTENSION, PULMONARY; INFLAMMATION; LIPID METABOLISM; LUNG; METABOLISM; PATHOLOGY; VASCULAR REMODELING; VASCULARIZATION; WISTAR RAT;

ANIMALS; ARACHIDONIC ACID; ARTERIOLES; FATTY ACIDS, UNSATURATED; HYPERTENSION, PULMONARY; INFLAMMATION; LIPID METABOLISM; LUNG; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MONOGLYCERIDES; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR REMODELING;

EID: 84906082306     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00814.2013     Document Type: Article

References (57)

1. Akiba S, Murata T, Kitatani K, Sato T. Involvement of lipoxygenase pathway in docosapentaenoic acid-induced inhibition of platelet aggregation. Biol Pharm Bull 23: 1293-1297, 2000.
2. Aoki H, Hisada T, Ishizuka T, Utsugi M, Kawata T, Shimizu Y, Okajima F, Dobashi K, Mori M. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun 367: 509-515, 2008.
3. Balabanian K, Foussat A, Dorfmuller P, Durand-Gasselin I, Capel F, Bouchet-Delbos L, Portier A, Marfaing-Koka A, Krzysiek R, Rimaniol AC, Simonneau G, Emilie D, Humbert M. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 165: 1419-1425, 2002.
4. Behr TM, Berova M, Doe CP, Ju H, Angermann CE, Boehm J, Willette RN. p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Curr Opin Investig Drugs 4: 1059-1064, 2003.
5. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 104: 11418-11423, 2007.
6. Broadfield EC, McKeever TM, Whitehurst A, Lewis SA, Lawson N, Britton J, Fogarty A. A case-control study of dietary and erythrocyte membrane fatty acids in asthma. Clin Exp Allergy 34: 1232-1236, 2004.
7. Christensen E, Woldseth B, Hagve TA, Poll-The BT, Wanders RJ, Sprecher H, Stokke O, Christophersen BO. Peroxisomal beta-oxidation of polyunsaturated long chain fatty acids in human fibroblasts. The polyunsaturated and the saturated long chain fatty acids are retroconverted by the same acyl-CoA oxidase. Scand J Clin Lab Invest Suppl 215: 61-74, 1993.
8. Christman JW, Sadikot RT, Blackwell TS. The role of nuclear factorkappa B in pulmonary diseases. Chest 117: 1482-1487, 2000.
9. Clarke SD, Jump DB. Regulation of gene transcription by polyunsaturated fatty acids. Prog Lipid Res 32: 139-149, 1993.
10. Connor WE. Importance of n-3 fatty acids in health and disease. Am J Clin Nutr 71: 171S-175S, 2000.
11. Dalli J, Serhan CN. Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120: E60-E72, 2012.
12. Dalli J, Colas RA, Serhan CN. Novel n-3 immunoresolvents: structures and actions. Sci Rep 3: 1940, 2013.
13. De Caterina R, Cybulsky MI, Clinton SK, Gimbrone MA Jr, Libby P. The omega-3 fatty acid docosahexaenoate reduces cytokine-induced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 14: 1829-1836, 1994.
14. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 22: 358-363, 2003.
15. Fortin S. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof, and uses thereof. US patents 819690 and 8222295, 2012.
16. Fortin S. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. Canadian patents 2672513 (2008) and 2677670 (2010) and US patent 8119690 (2011).
17. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, Weed DA, Gelrud A, Regan MM, Laposata M, Alvarez JG, O'Sullivan BP. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 350: 560-569, 2004.
18. Giudetti AM, Cagnazzo R. Beneficial effects of n-3 PUFA on chronic airway inflammatory diseases. Prostaglandins Other Lipid Mediat 99: 57-67, 2012.
19. Goldman DW, Pickett WC, Goetzl EJ. Human neutrophil chemotactic and degranulating activities of leukotriene B5 (LTB5) derived from eicosapentaenoic acid. Biochem Biophys Res Commun 117: 282-288, 1983.
20. Gotoh N, Nagao K, Onoda S, Shirouchi B, Furuya K, Nagai T, Mizobe H, Ichioka K, Watanabe H, Yanagita T, Wada S. Effects of three different highly purified n-3 series highly unsaturated fatty acids on lipid metabolism in C57BL/KsJ-db/db mice. J Agric Food Chem 57: 11047-11054, 2009.
21. Holub BJ, Swidinsky P, Park E. Oral docosapentaenoic acid (22:5n-3) is differentially incorporated into phospholipid pools and differentially metabolized to eicosapentaenoic acid in tissues from young rats. Lipids 46: 399-407, 2011.
22. Humbert M, Monti G, Brenot F, Sitbon O, Portier A, Grangeot-Keros L, Duroux P, Galanaud P, Simonneau G, Emilie D. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 151: 1628-1631, 1995.
23. Humbert M, Yaici A, Sztrymf B, Montani D. Pulmonary hypertension: from genetics to treatments. Rev Pneumol Clin 60: 196-201, 2004.
24. Jeffery TK, Morrell NW. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 45: 173-202, 2002.
25. Jung UJ, Baek NI, Chung HG, Jeong TS, Lee KT, Lee MK, Choi MS. Antilipogenic and hypolipidemic effects of ethanol extracts from two variants of Artemisia princeps Pampanini in obese diabetic mice. J Med Food 12: 1238-1244, 2009.
26. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 3: 221-227, 2002.
27. Kaur G, Cameron-Smith D, Garg M, Sinclair AJ. Docosapentaenoic acid (22:5n-3): a review of its biological effects. Prog Lipid Res 50: 28-34, 2011.
28. 14C]EPA in rats. Br J Nutr 109: 441-448, 2012.
29. Kaur G, Sinclair AJ, Cameron-Smith D, Barr DP, Molero-Navajas JC, Konstantopoulos N. Docosapentaenoic acid (22:5n-3) down-regulates the expression of genes involved in fat synthesis in liver cells. Prostaglandins Leukot Essent Fatty Acids 85: 155-161, 2011.
30. Kishida E, Tajiri M, Masuzawa Y. Docosahexaenoic acid enrichment can reduce L929 cell necrosis induced by tumor necrosis factor. Biochim Biophys Acta 1761: 454-462, 2006.
31. Kortz L, Dorow J, Becker S, Thiery J, Ceglarek U. Fast liquid chromatography-quadrupole linear ion trap-mass spectrometry analysis of polyunsaturated fatty acids and eicosanoids in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 927: 209-213, 2013.
32. Lepage G, Roy CC. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 27: 114-120, 1986.
33. Lesprit P, Godeau B, Authier FJ, Soubrier M, Zuber M, Larroche C, Viard JP, Wechsler B, Gherardi R. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 157: 907-911, 1998.
34. Levy BD, Kohli P, Gotlinger K, Haworth O, Hong S, Kazani S, Israel E, Haley KJ, Serhan CN. Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness. J Immunol 178: 496-502, 2007.
35. Matsumori A. Anti-inflammatory therapy for heart failure. Curr Opin Pharmacol 4: 171-176, 2004.
36. McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galie N, Gibbs JS, Kim NH, Oudiz RJ, Peacock A, Provencher S, Sitbon O, Tapson VF, Seeger W. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 54: S97-S107, 2009.
37. Miller E, Kaur G, Larsen A, Loh SP, Linderborg K, Weisinger HS, Turchini GM, Cameron-Smith D, Sinclair AJ. A short-term n-3 DPA supplementation study in humans. Eur J Nutr 52: 895-904, 2013.
38. 2+ sensitivity in human pulmonary arteries. Am J Physiol Heart Circ Physiol 301: H1311-H1318, 2011.
39. Morin C, Fortin S, Cantin AM, Rousseau E. MAG-EPA resolves lung inflammation in an allergic model of asthma. Clin Exp Allergy 43: 1071-1082, 2013.
40. Morin C, Fortin S, Cantin AM, Sirois M, Sirois C, Rizcallah E, Rousseau E. Anti-cancer effects of a new docosahexaenoic acid monoacylglyceride in lung adenocarcinoma. Recent Pat Anticancer Drug Discov 8: 319-334, 2013.
41. Morin C, Guibert C, Sirois M, Echave V, Gomes MM, Rousseau E. Effects of ω-hydroxylase product on distal human pulmonary arteries. Am J Physiol Heart Circ Physiol 294: H1435-H1443, 2008.
42. Morin C, Rousseau E, Fortin S. Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. Prostaglandins Leukot Essent Fatty Acids 89: 203-213, 2013.
43. Phang M, Garg ML, Sinclair AJ. Inhibition of platelet aggregation by omega-3 polyunsaturated fatty acids is gender specific-Redefining platelet response to fish oils. Prostaglandins Leukot Essent Fatty Acids 81: 35-40, 2009.
44. Price LC, Montani D, Tcherakian C, Dorfmuller P, Souza R, Gambaryan N, Chaumais MC, Shao DM, Simonneau G, Howard LS, Adcock IM, Wort SJ, Humbert M, Perros F. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J 37: 813-822, 2011.
45. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 22: 659-661, 2008.
46. Rubin LJ. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med 166: 1308-1309, 2002.
47. Serhan CN, Petasis NA. Resolvins and protectins in inflammation resolution. Chem Rev 111: 5922-5943, 2011.
48. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 233: 674-688, 2008.
49. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, Walker C, Budd DC, Pepke-Zaba J, Morrell NW. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122: 920-927, 2010.
50. Spite M, Serhan CN. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 107: 1170-1184, 2010.
51. Stoffel W, Eker, Assad H, Sprecher H. Enzymatic studies on the mechanism of the retroconversion of C22-polyenoic fatty acids to their C20-homologues. Hoppe Seylers Z Physiol Chem 351: 1545-1554, 1970.
52. Tagawa H, Shimokawa H, Tagawa T, Kuroiwa-Matsumoto M, Hirooka Y, Takeshita A. Long-term treatment with eicosapentaenoic acid augments both nitric oxide-mediated and non-nitric oxide-mediated endothelium-dependent forearm vasodilatation in patients with coronary artery disease. J Cardiovasc Pharmacol 33: 633-640, 1999.
53. Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K. Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 161: 387-394, 2002.
54. Tiesset H, Pierre M, Desseyn JL, Guery B, Beermann C, Galabert C, Gottrand F, Husson MO. Dietary (n-3) polyunsaturated fatty acids affect the kinetics of pro-and antiinflammatory responses in mice with Pseudomonas aeruginosa lung infection. J Nutr 139: 82-89, 2009.
55. Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension. Vascul Pharmacol 45: 358-367, 2006.
56. Weerackody RP, Welsh DJ, Wadsworth RM, Peacock AJ. Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction. Am J Physiol Heart Circ Physiol 296: H1312-H1320, 2009.
57. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821, 2005.